Original Publication Date: 1 October, 2015
Publication / Source: International Journal of Hematologic Oncology
Authors: Kareem Jamani & Carolyn Owen
Recurrent chromosomal aberrations have long been recognized to influence prognosis in acute myeloid leukemia (AML), however, 50% of AML patients have a normal karyotype. The new millennium ushered in discoveries of gene mutations at the molecular level that predict outcome in patients with normal karyotype. Some recurrent mutations are already used in routine practice for AML risk stratification.